Clinical Trial

Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
DATE-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of tenecteplase combined with standard medications in acute ischemic stroke patients with medium vessel occlusion stroke within 24 hours of onset.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-12.
Trial Details
NCT Number NCT07469293
Lead Sponsor Southwest Hospital, China
Conditions Acute Ischemic Stroke
Enrollment 488 participants
Start Date 2026-03-25
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-20